Stock Events

Stock Events

Galderma Group 

€184.00
44
-€6.00-3.16% Monday 07:00

Statistics

Day High
184
Day Low
184
52W High
204
52W Low
145
Volume
8
Avg. Volume
8
Mkt Cap
43.16B
P/E Ratio
-
Dividend Yield
0.21%
Dividend
0.38

Upcoming

Dividends

0.21%Dividend Yield
Apr 26
€0.38
Apr 25
€0.07
Apr 25
€0.09
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
438.17%

Earnings

23JulExpected
Q4 2024
Q2 2025
Q4 2025
Q2 2026
0.83
1.24
1.65
2.06
Expected EPS
1.9773
Actual EPS
2.0563919999999998

Financials

11.78%Profit Margin
Profitable
2023
2024
2025
4.43BRevenue
521.7MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1GALD.MI. It's not an investment recommendation.
Nestle SA
14
NESN.SW
Amazon
12
AMZN
Novartis
12
NOVN.SW
Zurich Insurance Group
12
ZURN.SW

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson offers a wide range of skincare products through its consumer health division, directly competing with Galderma's offerings in the dermatological care market.
Novartis
NVS
Mkt Cap304.1B
Novartis, former parent company of Galderma, has a strong presence in the healthcare sector, including dermatology, competing in therapeutic areas similar to Galderma.
Pfizer
PFE
Mkt Cap162.16B
Pfizer competes in the pharmaceuticals sector including dermatology, offering products that overlap with Galderma’s therapeutic solutions.
Merck
MRK
Mkt Cap370.89B
Merck operates in the healthcare and pharmaceutical sectors with products that compete in dermatological conditions, a key area for Galderma.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol-Myers Squibb competes in various therapeutic areas including those that overlap with Galderma’s dermatology-focused portfolio.
Lilly(Eli) &
LLY
Mkt Cap1.02T
Eli Lilly competes in the pharmaceutical field with a focus on medical dermatology, offering treatments that can compete with Galderma’s products.
GSK
GSK
Mkt Cap99.96B
GlaxoSmithKline has a diversified healthcare portfolio that includes skin health products, competing with Galderma in the dermatology market.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca operates broadly in the pharmaceutical sector, including areas that compete with Galderma’s dermatological treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.22B
Regeneron Pharmaceuticals focuses on innovative treatments, including for skin diseases, which puts it in competition with Galderma’s dermatology products.

About

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Show more...
CEO
Country
Switzerland
ISIN
CH1335392721
WKN
000A407X6

Listings

MX
MX
GALDN.MX
F
DE
PY3.F
MU
DE
PY3.MU
STU
DE
PY3.STU

0 Comments

Share your thoughts

FAQ

What is Galderma Group stock price today?▼
The current price of 1GALD.MI is €184.00 EUR — it has decreased by -3.16% in the past 24 hours. Watch Galderma Group stock price performance more closely on the chart.
What is Galderma Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Borsa Italiana exchange Galderma Group stocks are traded under the ticker 1GALD.MI.
What is Galderma Group market cap?▼
Today Galderma Group has the market capitalization of 43.16B
When is the next Galderma Group earnings date?▼
Galderma Group is going to release the next earnings report on March 11, 2027.
What were Galderma Group earnings last quarter?▼
1GALD.MI earnings for the last quarter are 2.06 EUR per share, whereas the estimation was 1.98 EUR resulting in a +4% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Galderma Group revenue for the last year?▼
Galderma Group revenue for the last year amounts to 4.43B EUR.
What is Galderma Group net income for the last year?▼
1GALD.MI net income for the last year is 521.7M EUR.
Does Galderma Group pay dividends?▼
Yes, 1GALD.MI dividends are paid annual. The last dividend per share was 0.38 EUR. As of today, Dividend Yield (FWD)% is 0.21%.
In which sector is Galderma Group located?▼
Galderma Group operates in the Other sector.
When did Galderma Group complete a stock split?▼
Galderma Group has not had any recent stock splits.